Sign In
 
Register
 
Complaints
 
Contact
SEARCH  
 
 
   
 
   
   
   
 
PRODUCT DETAIL
 
   
 

FARENAX®

Composition
A Farenax® pack contains:
i.  3 round Sulfadoxine + Pyrimethamine tablets each containing 500 mg Sulfadoxine and 25 mg Pyrimethamine.
ii. 3 oblong Artesunate tablets each containing 200 mg Artesunate base.

Properties, effects:
Farenax® exerts it’s antimalarial effect through the synergistic activity of all its components
(Sulfadoxine, Pyrimethamine and Artesunate). Sulfadoxine and Pyrimethamine acts by reciprocal potentiation of its two components, achieved by a sequential blockage of two enzymes involved in the biosynthesis of folic acid in parasites.

Artesunate has a rapid and potent schizonticidal activity against malaria parasites.  It has a peroxide bond which breaks up inside the parasite forming singlet oxygen (free radicals) which  exert a direct cytotoxic effect on the cells.  By virtue of this marked synergistic action, Farenax® is also effective against strains that are resistant to other commonly used antimalarial drugs, such as chloroquine and other 4-aminoquinoline derivatives, proguanil, Pyrimethamine and Sulfonamide-Pyrimethamine combinations.

Farenax® being an Artemisinin based Combination product, has a marked reduction of the likelihood of resistance development to the individual components.

Pharmacokinetics:
Following oral administration, Farenax® is rapidly absorbed, peak plasma levels for Sulfadoxine is reached after about 16 hours, Pyrimethamine after 2 to 4 hours and Artesunate in 1 - 2 hours.

In humans, binding to plasma protein is 87.6% for Sulfadoxine, 92.5% for Pyrimethamine and 50% for Artesunate.
Elimination half - life is 200 hours for sulfadoxine, 100 hours for Pyrimethamine and approximately 2 to 4 hours for Artesunate.  Artesunate is metabolised in the liver by hydrolysis giving rise to dihydroartemisinin, which is also effective against malaria by the same mechanism of action.

Indications:
Treatment of all forms of malaria due to Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.

Contraindications:
Farenax® is contraindicated in patients who are hypersensitive to any of its active substances or to any of its excipients.
Fetal malformation has been observed in rats when Sulfadoxine + Pyrimethamine alone was administered in early pregnancy, this was due to Pyrimethamine, the folic acid antagonist.  Although Pyrimethamine is not known to cause fetal malformation in humans.  Farenax® should not be administered in the first trimester of pregnancy.

Dosage and administration:
Adult dose: (Above 12 years)
3 round  tablets of Sulfadoxine + Pyrimethamine and 1 oblong caplet of Artesunate to be taken at once on the first day, then 1 oblong caplet of Artesunate on the 2nd and 3rd day.